CVRx, Inc. (CVRX)

In the past six months, CVRx reported Q3 2025 revenue of $14.7 million and Q4 2025 revenue of $16 million, resulting in a full-year 2025 revenue of $56.7 million. The transition to Category 1 CPT codes took effect on January 1, 2026, which is expected to reduce friction in the prior authorization process. The FDA approved the design for the BENEFIT-HF trial in November 2025. Despite these positive developments, the stock price has seen fluctuations, with a share price of $9.01 as of April 2, 2026.

CVRx's products and services experience demand seasonality, with the company noting a typical Q1 dip in revenue performance.

CVRx, Inc. is a commercial-stage medical device company focused on minimally invasive neuromodulation solutions for cardiovascular diseases. Their flagship product, Barostim, is an FDA-approved implantable device that uses electrical pulses to target the baroreflex mechanism for managing heart failure and resistant hypertension.

CVRx's global headquarters are in Minneapolis, Minnesota, with the majority of revenue from the USA market. Barostim is commercially available in over 20 countries and is under clinical evaluation in the United States and Germany. As of Q3 2025, CVRx had expanded its U.S. commercial footprint to 250 active implanting centers, with 53 sales territories in the U.S. as of December 31, 2025.

CVRx has maintained a generally positive brand reputation among financial analysts, with a consensus "Moderate Buy" recommendation. There were some downgrades in May 2025 following a Q1 2025 sales miss. CVRx is recognized as a pioneer in neuromodulation technologies for chronic diseases and is committed to ongoing innovation.

CVRx, Inc. has a mixed ownership structure including institutional, insider, and retail investors. Institutional investors hold approximately 39.71% to 57.85% of the company's stock. Johnson & Johnson is the largest individual shareholder, owning 7.52 million shares, representing 28.58% of the company. Insiders collectively own about 28.73% of the company.